📊 TYRA Key Takeaways
Is Tyra Biosciences, Inc. (TYRA) a Good Investment?
Tyra Biosciences is a pre-revenue biopharmaceutical company with a fortress balance sheet ($85M cash, minimal debt) but significant fundamental concerns including substantial operating losses (-$42M), negative cash flow (-$32.7M FCF), and deteriorating profitability trends YoY (-38.7%). Strong financial runway provides operational flexibility, but lacks revenue validation and shows accelerating cash burn.
Why Buy Tyra Biosciences, Inc. Stock? TYRA Key Strengths
- Exceptional balance sheet strength with $85M cash and zero debt
- Minimal liabilities ($24.5M) relative to $412M asset base
- Extreme liquidity position (20.49x current ratio) supports extended R&D runway
- Significant stockholders equity ($387.6M) provides capital cushion
TYRA Stock Risks: Tyra Biosciences, Inc. Investment Risks
- Pre-revenue company with no commercial product validation or sales
- Operating cash burn of -$32.6M annually with only ~2.6 years runway at current burn rate
- Net losses deteriorating YoY (-38.7%), indicating spending acceleration without offsetting revenue growth
- Early-stage biopharma execution risk: clinical failures, regulatory delays, or financing challenges could deplete runway
- Insider activity (9 Form 4 filings/90 days) warrants monitoring for potential dilution or unresolved concerns
Key Metrics to Watch
- Monthly operating cash burn rate and cash runway estimate
- Clinical trial progress, milestones, and regulatory approval timelines
- R&D efficiency metrics and cost per development milestone
- Quarterly cash balance and any financing activity (equity raises, debt issuance)
Tyra Biosciences, Inc. (TYRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 20.49x current ratio provides a solid financial cushion.
TYRA Profit Margin, ROE & Profitability Analysis
TYRA vs Healthcare Sector: How Tyra Biosciences, Inc. Compares
How Tyra Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tyra Biosciences, Inc. Stock Overvalued? TYRA Valuation Analysis 2026
Based on fundamental analysis, Tyra Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tyra Biosciences, Inc. Balance Sheet: TYRA Debt, Cash & Liquidity
TYRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tyra Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.51 indicates the company is currently unprofitable.
TYRA Revenue Growth, EPS Growth & YoY Performance
Tyra Biosciences, Inc. Dividends, Buybacks & Capital Allocation
TYRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tyra Biosciences, Inc. (CIK: 0001863127)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TYRA
What is the AI rating for TYRA?
Tyra Biosciences, Inc. (TYRA) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TYRA's key strengths?
Claude: Exceptional balance sheet strength with $85M cash and zero debt. Minimal liabilities ($24.5M) relative to $412M asset base.
What are the risks of investing in TYRA?
Claude: Pre-revenue company with no commercial product validation or sales. Operating cash burn of -$32.6M annually with only ~2.6 years runway at current burn rate.
What is TYRA's revenue and growth?
Tyra Biosciences, Inc. reported revenue of N/A.
Does TYRA pay dividends?
Tyra Biosciences, Inc. does not currently pay dividends.
Where can I find TYRA SEC filings?
Official SEC filings for Tyra Biosciences, Inc. (CIK: 0001863127) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TYRA's EPS?
Tyra Biosciences, Inc. has a diluted EPS of $-0.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TYRA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Tyra Biosciences, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TYRA stock overvalued or undervalued?
Valuation metrics for TYRA: ROE of -10.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TYRA stock in 2026?
Our dual AI analysis gives Tyra Biosciences, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TYRA's free cash flow?
Tyra Biosciences, Inc.'s operating cash flow is $-32.6M, with capital expenditures of $88.0K.
How does TYRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.1% (avg: 15%), current ratio 20.49 (avg: 2).